Evaluating Faricimab for treating eye diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the efficacy and safety of Faricimab in treating adults with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Participants will receive monthly intravitreal injections of Faricimab for three months, with bi-weekly clinic visits for monitoring. The study focuses on improving visual acuity and understanding any medical issues related to the treatment. Faricimab is a bispecific antibody targeting both VEGF-A and Ang-2, potentially offering enhanced treatment outcomes for these retinal conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Chinese patients aged 18 years or older and of any gender;
2. Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA;
3. Patients whose decision to receive treatment with faricimab was made prior to and independent of study participation;
4. Patients who have received at least one treatment with faricimab during the course of the study;
5. have signed an informed consent form.

Exclusion Criteria:

1. Active ocular inflammation or suspected active ocular infection in either eye;
2. Receipt of any other anti-VEGF therapy after faricimab;
3. Patient is unable to provide clinical data (visual acuity and OCT images) within 2 weeks (14 days) prior to receiving the initial faricimab injection;
4. Currently participating in any other clinical trial.

Where it's running

• 2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China
  Hanzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Panpan Ye, doctor
• Email: yepanpan@zju.edu.cn
• Phone: +86 13806506267

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blepharoptosis After Repeated Anti-VEGF Injections in One Eye

  This study tests whether repeated intravitreal anti-VEGF injections in one eye affect eyelid position compared with the untreated fellow eye.

  Recruiting Fatih Sultan Mehmet Training and Research Hospital · Istanbul · NCT07821450

• Personalized treat-and-extend faricimab regimen for treatment-naive polypoidal choroidal vasculopathy

  This tests whether a personalized treat-and-extend dosing schedule of faricimab (Vabysmo) helps people with newly diagnosed polypoidal choroidal vasculopathy keep or improve their vision.

  Recruiting Phase 3 Yeungnam University College of Medicine · Daegu, Namgu · NCT07461441

• RO7823653 injections, alone or with faricimab, for diabetic macular edema

  This research tests injections of RO7823653, given alone or with faricimab, in people with diabetic macular edema to see if the medication is safe and how the eye handles it.

  Recruiting at 12 sites Phase 1 Genentech, Inc. · Peoria, Arizona and 11 other locations · NCT07425522

• Watching a short video before anti-VEGF eye injections

  This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07002372

• Switching patients with AMD from ranibizumab or aflibercept to faricimab

  This study is testing if switching people with age-related macular degeneration from their current eye injections to a new treatment called faricimab can improve their vision and reduce the number of injections they need.

  Recruiting Nantes University Hospital · Nantes, Nantes · NCT06271330

• Understanding Age-Related Macular Degeneration and Its Progression

  This study looks at how age-related macular degeneration develops and progresses by comparing people with the condition to healthy individuals, using non-invasive tests and personal feedback.

  Recruiting Center for Eye Research Australia · East Melbourne, Victoria · NCT04739319

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.